Exhibit 99.1 Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance MENLO PARK, Calif., August 1, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the second quarter ended June 30, 2024, and narrowed financial guidance for full ...

MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 ...

MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its first Sustainability Report, highlighting the Company's sustainability activities, performance, and results from the last three years. Environmental Initiatives: Details of Sight Sciences' effort ...

© 2024 Sight Sciences. All rights reserved. The Sustainability Report includes: Governance Practices: Disclosure of Sight Sciences' governance framework, ethical standards, and commitment to transparency and accountability, including reporting on information security breaches. For additional information and highlights, please see the full Sustainability Report, which can be found here. All Environmental, Social, and Governance ("ESG") practices are overseen by the Company's Nominating and Corporate Governan ...

Core Insights - Sight Sciences, Inc. announced the twelve-month results from the SAHARA trial, demonstrating the effectiveness of TearCare in treating dry eye disease (DED) compared to Restasis [1][3][11] Study Results - Patients previously treated with Restasis showed clinically meaningful improvements in DED symptoms after switching to TearCare, with benefits lasting for six months post-treatment [2][6] - Phase 2 of the SAHARA trial confirmed that TearCare is effective regardless of prior Restasis treatment, indicating its potential as both a primary and secondary treatment option for DED [3][4] - The trial included 345 subjects in Phase 1 and 163 patients crossed over to TearCare in Phase 2, with significant improvements in tear break-up time (TBUT) and other dry eye measures [4][5] Statistical Findings - TBUT improved by 1.1 seconds at three months and 0.6 seconds at twelve months after switching to TearCare, both statistically significant (p<.001) [8] - Other measures, including meibomian gland secretion score (MGSS) and ocular surface disease index (OSDI), also showed significant improvements post-treatment [8][10] - The study reported that mean values for TBUT, MGSS, and other ocular signs improved significantly compared to baseline measurements [10][11] Future Directions - The SAHARA trial will continue into Phase 3, which aims to provide long-term data on the durability and effectiveness of TearCare over a two-year period [11]

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops ("Restasis") had additional ...

Key findings reported in the study include: MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) s ...

Core Insights - Sight Sciences, Inc. announced new findings from the ROMEO study, indicating that the OMNI Surgical System is effective in treating advanced glaucoma patients, challenging previous beliefs about treatment efficacy in severe cases [1][2][3] Group 1: Study Findings - The analysis showed that ab interno canaloplasty combined with trabeculotomy using OMNI effectively lowered intraocular pressure (IOP) and reduced medication usage across all severity levels of glaucoma [2][5] - 70% of eyes experienced a reduction in IOP at 12 months, with 92% achieving IOP levels of 18 mmHg or less [5] - The mean IOP at month 12 ranged between 14 mmHg and 16 mmHg, consistent across different severity groups [5] - A significant percentage of patients (50% to 69%) showed a reduction of at least one medication, indicating the treatment's effectiveness [5] - Regression analysis indicated no significant relationship between month 12 IOP and visual field loss, suggesting consistent treatment outcomes regardless of disease severity [5] Group 2: Study Design and Demographics - The ROMEO study was a retrospective case series approved by an Institutional Review Board, conducted at eleven ophthalmology practices in the U.S. [3] - The majority of participants (95%) had primary open-angle glaucoma and underwent the implant-free OMNI procedure, which is FDA-cleared for canaloplasty and trabeculotomy [3][4] Group 3: Company Vision and Technology - Sight Sciences aims to transform eyecare through innovative, minimally invasive technologies that address the underlying causes of prevalent eye diseases [8] - The OMNI Surgical System is indicated for reducing IOP in adult patients with primary open-angle glaucoma and is CE marked for additional procedures [8] - The company is committed to providing effective treatment options for glaucoma patients at all disease stages, reinforcing its dedication to advancing eyecare technology [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 (St ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants David Saxon - Needham & Company James Beers - William Blair Thomas Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2024 Earnings Res ...